ArticleSmall science2026
Tunable Fabrication of 2D-Layered Magnesium Nanosilicates With Hemostatic Properties.
Article in Small science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tunable fabrication of inorganic two-dimensional (2D) nanoclays is of substantial interest for fundamental studies and biomedical applications. Despite extensive work on inorganic biomaterials, layered silicate nanoclays remain a comparatively underexplored class of 2D systems. Here, we report an optimized hydrothermal method for the tunable fabrication of 2D layered magnesium nanosilicates (nSi). This approach yields disc-like nanoclays with lateral dimensions of ~20-50 nm and thickness of ~1-2 nm. The nanosilicates exhibit rapid cellular internalization, controlled therapeutic release in vitro, and the ability to form shear-thinning, thixotropic gels. Proteomic analyses indicate the formation of a protein corona enriched in factors associated with blood coagulation, consistent with in vitro clotting assays showing a concentration-dependent reduction in clotting time, with decreases of ~50% at higher doses. In an in vivo rat liver-laceration model, nanosilicate treatment reduced clotting time by ~75% and blood loss by ~45%, compared with controls. Collectively, these findings establish a tunable route for fabricating 2D-layered magnesium nanosilicates and suggest their potential utility in hemostasis and wound-management applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.